E-211

E-2101 is a novel antispastic agent. E-2101 is a competitive CYP2C19 and CYP2D6 inhibitor with Ki values of 15 and 48 μM, respectively. E-2101 is metabolized by Cytochromes P450 to form monohydroxylated (M1 and M2), dihydroxylated (M3), and N-dealkylated metabolites (M4) . E-2101 can be used in the research of skeletal muscle spasm[1].

265667-22-9

12352005

Cytochrome P450

Metabolic Enzyme/Protease

Others

O=C(NC)CC1=CC2=C(C=C1)C=CN2C3CCN(CCC4=CC=CC=C4F)CC3

C24H28FN3O

393.50

[1]Zhang ZY, et al. In vitro interactions between a potential muscle relaxant E2101 and human cytochromes P450. Drug Metab Dispos. 2002 Jul;30 (7) :805-13. |[2]Kushida, et al. Solid state characterization of E2101, a novel antispastic drug. J Pharm Sci. 2002 Oct;91 (10) :2193-202.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-19379/

Reference compound1

Phase 1

CYP2